Phase II trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer.
Ulka N VaishampayanArchana ThakurWei ChenAbhinav DeolMeera PatelKimberlee DobsonBrenda DickowDana L SchalkAmy SchienschangSarah A WhitakerAmanda PolendJoseph A FontanaElisabeth I HeathLawrence G LumPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The safety and promising efficacy makes this combination worthy of future investigation in mCRPC.